STING-dependent activation of Natural Killer cells by viral and tumor DNA

病毒和肿瘤 DNA 对自然杀伤细胞的 STING 依赖性激活

• 批准号: 10561647
• 负责人: DAVID H RAULET
• 金额: $ 45.3万
• 依托单位: UNIVERSITY OF CALIFORNIA BERKELEY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-06-01 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10561647
• 关键词: Alleles; Antigen-Presenting Cells; Antitumor Response; Antiviral Response; Binding; Bone Marrow; CRISPR interference; Cancer Model; Cells; Chimera organism; Cre driver; Critical Pathways; DNA; DNA Viruses; DNA biosynthesis; Data; Data Analyses; Defect; Dendritic Cells; Dinucleoside Phosphates; Enzymes; Event; Failure; Genetic Engineering; Genetic Transcription; Genetically Engineered Mouse; Graft Rejection; Herpesviridae; Immune; Immune response; Immune signaling; In Vitro; Infection; Injections; Interferon Type I; Interferons; Investigation; Knockout Mice; Macrophage; Malignant Neoplasms; Mammalian Cell; Mediating; Mediator; Membrane Transport Proteins; Modeling; Mus; NK Cell Activation; Natural Killer Cells; Neoplasm Transplantation; Pathway interactions; Periodicity; Process; Production; Productivity; Proteins; Research; Role; SLC19A1 gene; Series; Shapes; Signal Pathway; Signal Transduction; Site; Stimulator of Interferon Genes; Sting Injury; T cell response; T-Lymphocyte; Testing; Viral; Viral Cancer; Virus; Virus Diseases; anti-tumor immune response; cancer cell; cancer immunotherapy; cell transformation; conditional knockout; cytokine; genetic approach; genome-wide; immune activation; in vivo; inhibitor; intercellular communication; neoplastic cell; neutrophil; novel; novel strategies; pathogen; prevent; receptor; response; small molecule; treatment response; tumor; tumor DNA; tumor microenvironment; viral DNA

The cGAS-STING pathway senses cytosolic DNA in infected cells and cancer cells and triggers production of type I interferon and other cytokines, thus eliciting immune responses. Deficiency in the pathway prevents T cell responses to several viruses and to transplanted tumor lines. Our new results show that the pathway is critical for activating spontaneous NK cell responses against cancer, and virus infections. Furthermore, in probing the underlying mechanisms, our research has uncovered a new cellular mechanism whereby cGAS and STING activate immune responses. Using genetic approaches, we found that the NK response to transferred tumor cells depends on cGAS expression in tumor cells and STING expression in host cells. We interpret these data to indicate that cGAS activation is the key event that occurs in infected or transformed cells resulting in the production of the cyclic dinucleotide cGAMP. cGAMP is then transferred from the infected/transformed cells to other immune cells, such as antigen presenting cells, which are induced to initiate the immune response. Hence, we propose that cGAMP transfer between cells is a fundamental mechanism in immune activation. In considering how cGAMP is transferred between cells, we hypothesized that specific membrane transporters must play a role. Using a genome-wide CRISPRi screen, we identified a transporter molecule that specifically imports cGAMP into cells. Using a series of knockout mice and conditional knockout mice, and cellular manipulations and transfers, we propose to test the requirement of cGAS-STING signaling in NK and T cell responses to cancer and DNA viruses, the generality of the requirement of the transfer mechanism in viral infections and cancer models and for T cell and NK cell responses, the roles of the newly identified transporters in the process, and to define the specific cells that must import the cGAMP for immune responses to occur. Specifically, we will: (1) Determine the sites of action of cGAMP and STING and intercellular transfer of cGAMP in anti-viral responses, including NK and T cell responses; (2) Determine sites of action of cGAMP and STING and intercellular transfer of cGAMP in T cell responses to cancer, in transfer models and GEM cancer models; (3) Determine roles of cGAMP transporters in anti-viral and anti-tumor and immune responses. Using conditional knockout mice and inhibitor studies, we will test their function in anti-herpesvirus and anti-tumor responses, including a GEM model of cancer.

cGAS-STING途径感测受感染细胞和癌细胞中的胞质DNA，并触发 I型干扰素和其他细胞因子，从而引发免疫应答。该途径的缺陷阻止T 细胞对几种病毒和移植肿瘤系的反应。我们的新结果表明， 对于激活针对癌症和病毒感染的自发NK细胞应答至关重要。更以 探索潜在的机制，我们的研究发现了一种新的细胞机制， 和STING激活免疫反应。使用遗传学方法，我们发现NK细胞对 转移的肿瘤细胞依赖于肿瘤细胞中的cGAS表达和宿主细胞中的STING表达。我们 解释这些数据以表明cGAS活化是发生在感染或转化细胞中的关键事件 从而产生环状二核苷酸cGAMP。然后将cGAMP从 感染/转化的细胞转化为其他免疫细胞，如抗原呈递细胞，其被诱导启动免疫应答。 免疫反应。因此，我们认为细胞之间的cGAMP转移是一个基本的 免疫激活机制。在考虑cGAMP如何在细胞之间转移时，我们假设 特定的膜转运蛋白必须发挥作用。使用全基因组CRISPRi筛选，我们发现了一种 特异性地将cGAMP输入细胞的转运分子。使用一系列基因敲除小鼠， 条件敲除小鼠，细胞操作和转移，我们建议测试的要求， NK和T细胞对癌症和DNA病毒应答中的cGAS-STING信号传导， 病毒感染和癌症模型中的转移机制以及T细胞和NK细胞的需要 反应，新鉴定的转运蛋白在该过程中的作用，并定义特定的细胞， 必须输入cGAMP才能发生免疫反应。具体而言，我们将：（1）确定 cGAMP和STING的作用以及cGAMP在抗病毒应答中的细胞间转移，包括NK （2）确定cGAMP和STING的作用位点以及cGAMP和STING的细胞间转移。 在转移模型和GEM癌症模型中，cGAMP在T细胞对癌症的应答中的作用; cGAMP转运蛋白在抗病毒和抗肿瘤以及免疫应答中的作用。使用条件性基因敲除小鼠 和抑制剂的研究，我们将测试它们在抗疱疹病毒和抗肿瘤反应中的功能，包括GEM 癌症模型。